DK1976564T3 - Immun-rna-konstruktioner - Google Patents

Immun-rna-konstruktioner Download PDF

Info

Publication number
DK1976564T3
DK1976564T3 DK06841574.4T DK06841574T DK1976564T3 DK 1976564 T3 DK1976564 T3 DK 1976564T3 DK 06841574 T DK06841574 T DK 06841574T DK 1976564 T3 DK1976564 T3 DK 1976564T3
Authority
DK
Denmark
Prior art keywords
rna
nucleic acid
cell
cells
aptamer
Prior art date
Application number
DK06841574.4T
Other languages
English (en)
Inventor
Stefan Barth
Inga Neef
Ulrich Wüllner
Original Assignee
Fraunhofer Ges Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Ges Forschung filed Critical Fraunhofer Ges Forschung
Application granted granted Critical
Publication of DK1976564T3 publication Critical patent/DK1976564T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (13)

1. Forbindelse, som omfatter: - en målsøgningsdel, som specifikt binder sig til en sygdomsrelateret celleoverflademarkør, hvor målsøgningsdelen er en nukleinsyre valgt fra gruppen bestående af siRNA, et shRNA, et antisense-DNA eller -RNA, et dsRNA eller et miRNA; eller målsøgningsdelen er et polypeptid eller er valgt fra gruppen bestående af carbohydrater, lipider, små receptorligander, celleoverflade-carbohydratbindende proteiner valgt fra gruppen bestående af lectiner, lectiner af r-type og galectiner; ligander til differentieringsklynge (CD, cluster of differentiation)-antigenerne valgt fra gruppen bestående af CD30, CD40; cytokiner, kemokiner, kolonistimulerende faktorer, cytokiner af type 1, cytokiner af type 2, interferoner, interleukiner, lymfokinerog monokiner, - en nukleinsyredel, som specifikt inducerer celledød og er en nukleinsyredel, som specifikt hæmmer aktiviteten af eukaryot elongeringsfaktor 2 (eEF-2), - en linker, som kovalent forbinder målsøgningsdelen med nukleinsyredelen.
2. Forbindelse ifølge krav 1, hvor linkeren er en disulfidbinding, en phosphodi-esterbinding, en phosphothioatbinding, en amidbinding, en aminbinding, en thio-etherbinding, en etherbinding, en esterbinding eller en carbon-carbon-binding.
3. Forbindelse ifølge krav 1 eller 2, hvor målsøgningsdelen er mindst én apta-mer, navnlig mindst to aptamerer, et antistof, et diabody eller et fragment af et antistof.
4. Forbindelse ifølge et hvilket som helst af kravene 1-3, hvor den sygdomsrelaterede celleoverflademarkør er valgt fra gruppen bestående af CD-antigener, cytokinreceptorer, hormon receptorer, vækstfaktorreceptorer, ionpumper, kanaldannende proteiner, multimere ekstracellulære matrixproteiner, metalloproteaser, Fler3 og PSMA.
5. Forbindelse ifølge krav 1, som omfatter en aptamer og en nukleinsyre, såsom RNA, der er forbundet ved hjælp af en phosphodiester- eller en phospho-thioatbinding.
6. Forbindelse ifølge krav 1, som omfatter et antistof og et RNA, der er forbundet ved hjælp afen disulfidbinding.
7. Forbindelse ifølge krav 1, hvor nukleinsyredelen ikke inducerer celledød, men nedregulerer et specifikt nøgleelement i en regulatorvej i målcellen.
8. DNA, som koder for et RNA ifølge krav 5.
9. Celle, ikke-humant organ eller ikke-humant dyr, som er transficeret med et RNA eller DNA ifølge krav 6 eller 8.
10. Forbindelse ifølge et hvilket som helst af kravene 1-7, som endvidere omfatter en del, der muliggør oprensning og/eller påvisning af forbindelsen, letter translokation af forbindelsen ind i målcellen og/eller intracellulær separation deri og/eller aktiverer nukleinsyren.
11. Lægemiddel, som omfatter en forbindelse ifølge et hvilket som helst af kravene 1-7, et DNA ifølge krav 8 eller en celle ifølge krav 9.
12. Lægemiddel ifølge krav 11, hvor lægemidlet administreres lokalt eller systemisk eller i kombination med andre forbindelser, der forbedrer terapeutisk virkning.
13. Forbindelse ifølge et hvilket som helst af kravene 1 -7, DNA ifølge krav 8 eller celle ifølge krav 9 til anvendelse til behandling af proliferative cancer- eller ikkecancer-sygdomme, allergier, autoimmune sygdomme og/eller kronisk inflammation eller infektioner.
DK06841574.4T 2005-12-21 2006-12-21 Immun-rna-konstruktioner DK1976564T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05112660A EP1800695A1 (en) 2005-12-21 2005-12-21 Immuno-RNA-constructs
PCT/EP2006/070116 WO2007071777A2 (en) 2005-12-21 2006-12-21 Immuno-rna-constructs

Publications (1)

Publication Number Publication Date
DK1976564T3 true DK1976564T3 (da) 2016-06-06

Family

ID=36646002

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06841574.4T DK1976564T3 (da) 2005-12-21 2006-12-21 Immun-rna-konstruktioner

Country Status (7)

Country Link
US (1) US8829178B2 (da)
EP (2) EP1800695A1 (da)
CN (1) CN101340934B (da)
CA (1) CA2633776C (da)
DK (1) DK1976564T3 (da)
HK (1) HK1123728A1 (da)
WO (1) WO2007071777A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0712437A2 (pt) * 2006-06-01 2012-07-10 Univ Duke método de distribuição
US10842642B2 (en) 2009-04-16 2020-11-24 Nuvasive, Inc. Methods and apparatus of performing spine surgery
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012051152A2 (en) * 2010-10-12 2012-04-19 Kevin Ryan Novel dna templates for small rna production in mammalian cells
US9034839B2 (en) 2012-04-20 2015-05-19 Aptamir Therapeutics, Inc. miRNA modulators of thermogenesis
EP2880161A1 (en) * 2012-08-03 2015-06-10 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
WO2014030147A2 (en) * 2012-08-23 2014-02-27 Fundación Fraunhofer Chile Research Synthetic proteins based on dendrimers
US10711272B2 (en) * 2014-01-21 2020-07-14 City Of Hope CTLA-4 aptamer siRNA species
US10687956B2 (en) 2014-06-17 2020-06-23 Titan Spine, Inc. Corpectomy implants with roughened bioactive lateral surfaces
US20170182179A1 (en) * 2014-12-09 2017-06-29 Abbvie Inc. Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors
US11376660B2 (en) 2015-11-20 2022-07-05 Titan Spine, Inc. Processes for additively manufacturing orthopedic implants
TWI726940B (zh) 2015-11-20 2021-05-11 美商泰坦脊柱股份有限公司 積層製造整形外科植入物之方法
AU2017279550A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
AU2017305136A1 (en) 2016-08-03 2019-02-07 Titan Spine, Inc. Titanium implant surfaces free from alpha case and with enhanced osteoinduction
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
KR100208957B1 (ko) * 1990-04-25 1999-07-15 로렌스 티. 마이젠헬더 신규한 cc-1065 유사체
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
GB9200417D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
US5439819A (en) 1993-08-27 1995-08-08 The Regents Of The University Of California Chimeric protein tyrosine kinases
US5583034A (en) * 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US5935835A (en) 1996-10-11 1999-08-10 Smithkline Beecham Corporation Polynucleotide encoding human Myt-1 kinase clone
EP0973935A2 (en) * 1997-03-20 2000-01-26 Variagenics, Inc. Target genes for allele-specific drugs
US6346406B1 (en) * 1997-08-20 2002-02-12 University Of Medicine & Dentistry Of New Jersey Elongation factor-2 kinase (EF-2 kinase), and methods of use therefor
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
WO2001001137A1 (en) 1999-06-30 2001-01-04 Children's Medical Center Corporation Fusion protein and uses thereof
IL151910A0 (en) * 2000-04-12 2003-04-10 Implyx Ltd Compositions for drug delivery
DE50112965D1 (de) 2000-04-22 2007-10-18 Pharmedartis Gmbh Apoptotika
US20030190635A1 (en) * 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US20050153915A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
US20050159381A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
EP2415486B1 (en) * 2001-05-18 2017-02-22 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050176024A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA)
JP2004535202A (ja) 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション アポトーシス促進性蛋白質を含む治療剤
AU2003213047A1 (en) 2002-02-13 2003-09-04 Medbridge, Inc. Protein carrier system for therapeutic oligonucleotides
EP1741781A3 (en) * 2002-02-20 2007-06-06 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20060292651A1 (en) 2002-10-03 2006-12-28 Alexandre Juillerat Protein labelling with oº-alkylguanine-dna alkyltrnsferase
WO2004044141A2 (en) * 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Conjugated oligomeric compounds and their use in gene modulation
CA2506714A1 (en) 2002-11-26 2004-06-10 University Of Massachusetts Delivery of sirnas
WO2004078215A2 (en) 2003-02-28 2004-09-16 The Board Of Trustees Of The University Of Illinois Use of antibody conjugated deoxycytidine kinase for adept
AU2004242249A1 (en) 2003-05-23 2004-12-02 Epfl-Ecole Polytechnique Federale De Lausanne Methods for protein labeling based on acyl carrier protein
EP1682661A2 (en) * 2003-10-23 2006-07-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US20050148535A1 (en) * 2003-10-30 2005-07-07 Lacasse Eric IAP nucleobase oligomers and oligomeric complexes and uses thereof
US20050234000A1 (en) 2003-12-12 2005-10-20 Mitchell Gordon S SiRNA delivery into mammalian nerve cells
EP1730298B1 (en) 2004-03-02 2015-11-11 EPFL Ecole Polytechnique Fédérale de Lausanne Specific substrates for o6-alkylguanine-dna alkyltransferase
EP1737879B1 (en) * 2004-04-19 2012-10-10 Archemix LLC Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
WO2006021553A1 (en) 2004-08-23 2006-03-02 Covalys Biosciences Ag Method for protein purification and labeling based on a chemoselective reaction
EP1874738B1 (en) 2005-04-27 2016-06-29 Covalys Biosciences AG Pyrimidines reacting with o6-alkylguanine-dna alkyltransferase
CA2628113A1 (en) * 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
EP1882688A1 (en) 2006-07-25 2008-01-30 EPFL Ecole Polytechnique Fédérale de Lausanne Labelling of fusion proteins with synthetic probes

Also Published As

Publication number Publication date
CN101340934B (zh) 2013-04-24
US20090304717A1 (en) 2009-12-10
CN101340934A (zh) 2009-01-07
EP1976564A2 (en) 2008-10-08
HK1123728A1 (en) 2009-06-26
CA2633776A1 (en) 2007-06-28
WO2007071777A3 (en) 2007-11-22
EP1800695A1 (en) 2007-06-27
CA2633776C (en) 2018-03-06
US8829178B2 (en) 2014-09-09
EP1976564B1 (en) 2016-02-24
WO2007071777A2 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
DK1976564T3 (da) Immun-rna-konstruktioner
Kruspe et al. Aptamer-siRNA chimeras: discovery, progress, and future prospects
US10041071B2 (en) Cell-type specific aptamer-siRNA delivery system for HIV-1 therapy
Kotula et al. Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells
Mayer The chemical biology of aptamers
Xiao et al. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection
Dua et al. Nucleic acid aptamers targeting cell-surface proteins
Winkler et al. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins
Wullner et al. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2
Sivakumar et al. Targeted siRNA delivery using aptamer‐siRNA chimeras and aptamer‐conjugated nanoparticles
CA2768598A1 (en) Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
US20110197292A1 (en) Delivery method
Chen et al. Discovery of aptamer ligands for hepatic stellate cells using SELEX
CA2617561A1 (en) Multivalent rna nanoparticles for delivery of active agents to a cell
Klein et al. Centyrin ligands for extrahepatic delivery of siRNA
Winkler Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides
Hussain et al. An aptamer–siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing αvβ3 integrin
KR101678876B1 (ko) 복합 유전자를 표적하는 ｓｉＲＮＡ 다중 접합체 및 이의 제조방법
Wang et al. Synthetic α-l-Threose nucleic acids targeting BcL-2 show gene silencing and in Vivo antitumor activity for cancer therapy
Rosch et al. Albumin-binding aptamer chimeras for improved siRNA bioavailability
JP5252622B2 (ja) 高いヌクレアーゼ耐性と優れたｒｎａ干渉効果を発現可能な二本鎖ｒｎａ
Vorhies et al. Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics
Laufer et al. Selected strategies for the delivery of siRNA in vitro and in vivo
LT et al. IMMUNO-RNA KONJUGATE IMMUNO-RNA CONJUGUES
Wochner et al. Characterisation of aptamers for therapeutic studies